Vaxcyte, Inc.
Clinical trials sponsored by Vaxcyte, Inc., explained in plain language.
A biopharmaceutical company developing vaccines to prevent bacterial infections.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New pneumonia vaccine VAX-31 aims to boost protection in older adults
⭐️ VACCINE ⭐️ OngoingThis study tests a new vaccine called VAX-31 in adults aged 50 and older who have already received a pneumonia vaccine. The goal is to see if VAX-31 is safe and triggers a strong immune response. About 752 participants will receive either VAX-31 or an active comparator vaccine, a…
Phase: PHASE3 • Sponsor: Vaxcyte, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 02, 2026 00:00 UTC
-
New baby vaccine aims to beat pneumonia: VAX-31 trial underway
⭐️ VACCINE ⭐️ OngoingThis study tests a new vaccine called VAX-31 to protect babies against pneumococcal disease, which can cause pneumonia and meningitis. About 900 healthy infants will receive four doses of VAX-31 or an existing vaccine starting at 2 months old. Researchers will check for side effe…
Phase: PHASE2 • Sponsor: Vaxcyte, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:32 UTC
-
New combo shot study: could VAX-31 plus flu vaccine be a Game-Changer for seniors?
Prevention OngoingThis study tests a new vaccine called VAX-31, which protects against 31 types of pneumonia-causing bacteria. It is given together with the seasonal flu shot to healthy adults aged 50 and older. The goal is to see if giving both vaccines at the same time is safe and works as well …
Phase: PHASE3 • Sponsor: Vaxcyte, Inc. • Aim: Prevention
Last updated Jul 02, 2026 00:00 UTC
-
New vaccine aims to outsmart pneumonia bacteria
Prevention OngoingThis Phase 3 study is testing a new vaccine called VAX-31 in about 4,000 healthy adults aged 50 and older. The goal is to see if VAX-31 provides better immune protection against more strains of pneumococcal bacteria compared to two current vaccines, Prevnar 20 and Capvaxive. Rese…
Phase: PHASE3 • Sponsor: Vaxcyte, Inc. • Aim: Prevention
Last updated Jun 27, 2026 12:33 UTC